T Cell Therapy Preconditioning Using Cytokine Biomarker Thresholds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing T cell therapies for cancer treatment are difficult to predict their effectiveness in individual patients, necessitating a method to identify suitable candidates or prepare patients for optimal response.
Innovation Solution
Administer preconditioning agents to increase serum levels of cytokines such as IL-15, IL-7, and additional cytokines like MCP-1, CRP, PLGF, or IP-10, followed by T cell therapy when increased serum levels are detected, to create a more favorable environment for T cell proliferation and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cell therapy is administered to treat cancer, then the therapy may target and kill cancer cells, but it is difficult to predict whether the therapy will be effective in each patient
Solution Approach 1:
The patent applies preliminary action by measuring cytokine levels (IL-7, IL-15, IP-10, MCP-1, PLGF, CRP) in patient serum before administering T cell therapy. This pre-assessment allows clinicians to predict therapy effectiveness in advance, identifying suitable candidates before treatment begins, thereby resolving the unpredictability issue without adding complex evaluation procedures during treatment.
Solution Approach 2:
The patent utilizes parameter changes by monitoring specific cytokine concentration levels in patient serum as biomarkers. By establishing threshold values for these parameters (IL-7, IL-15, IP-10, MCP-1, PLGF, CRP), the patent transforms the subjective assessment of therapy suitability into an objective, quantifiable prediction system, improving reliability while maintaining simple measurement procedures.
2Reliability
If the patient's microenvironment is optimized for T cell proliferation by administering preconditioning agents, then T cell therapy effectiveness is improved, but additional treatment steps and time are required
Solution Approach 1:
The patent applies preliminary action by administering preconditioning agents (such as IL-7, IL-15, or chemotherapy agents like cyclophosphamide and fludarabine) before T cell therapy to optimize the patient's microenvironment. This prepares the patient's immune system in advance, creating favorable conditions for T cell proliferation and enhancing therapy effectiveness without extending the overall treatment timeline significantly.
Solution Approach 2:
The patent utilizes parameter changes by modifying the patient's physiological parameters through preconditioning agents. By adjusting cytokine levels, immune cell counts, and microenvironmental conditions before T cell administration, the patent creates optimal conditions for therapy success, resolving the effectiveness issue while the preconditioning duration is minimized through standardized protocols.
Data Source
AI summary
The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.